The Clinical Value of Soluble Urokinase Plasminogen Activator Receptor (suPAR) Levels in Autoimmune Connective Tissue Disorders.
The assessment of the general inflammatory condition of patients with autoimmune connective tissue disorders (ACTD) is a major challenge. The use of traditional inflammatory markers including CRP-levels and erythrocyte sedimentation rate (ESR) is limited by several preanalytical factors and their low specificities. Soluble urokinase plasminogen activator receptor (suPAR) is one of the novel candidate markers that is increasingly used in immune mediated disorders. In our studies we compared suPAR levels of patients with rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), systemic sclerosis (SSc) and ankylosing spondylitis with those of healthy controls. suPAR provided valuable clinical information on disease activity in RA, SLE and SSc. We identified a subgroup of remitted RA patients, who presented still clinical symptoms of inflammatory activity which correlated to high plasma suPAR (while ESR and CRP were normal). In SLE we established specific suPAR cut-off values that support the discrimination between patients with high and those with moderate SLE activity. In patients with SSc suPAR correlated with objective measures of lung and other complications. In the majority of ACTDs including SLE, SSc or RA, suPAR is seemingly a good biomarker that would provide valuable clinical information. However, before the introduction of this novel parameter in laboratory repertoire important issues should be elucidated. These include the establishment of appropriate and disease specific cutoff values, clarification of interfering preanalytical values and underlying conditions and declaration of age- and gender-specific reference ranges.
Department of Laboratory Medicine, Semmelweis University Budapest, Hungary; Bionic Innovation Centre, Budapest, Hungary.
Barna
B
Vasarhelyi
First Department of Obstetrics and Gynacology, Semmelweis University Budapest , Hungary.
Gergely
G
Toldi
Department of Rheumatology, Szent-Györgyi Albert Clinical Centre , Szeged, Hungary.
Attila
A
Balog
ankylosing spondylitis; autoimmune disease; biomarker; inflammation; rheumatoid arthritis; soluble urokinase plasminogen activator receptor; systemic lupus erythematosus; systemic sclerosis
Arthritis Rheum. 1997 Sep;40(9):1725
9324032
Arthritis Rheum. 2013 Nov;65(11):2737-47
24122180
Clin Chem Lab Med. 2013 Feb;51(2):327-32
22718576
J Intern Med. 2012 Sep;272(3):247-56
22755554
Lab Invest. 1999 Jun;79(6):717-22
10378514
Crit Care. 2011;15(1):R63
21324198
Arthritis Rheum. 1984 Apr;27(4):361-8
6231933
J Intern Med. 2014 Dec;276(6):651-8
24645798
J Intern Med. 2014 Dec;276(6):645-7
24734882
PLoS One. 2013;8(4):e60697
23565268
J Clin Invest. 2007 Mar;117(3):557-67
17332883
Dis Markers. 2009;27(3):157-72
19893210
Joint Bone Spine. 2013 Jan;80(1):96-8
22999906
Ann Rheum Dis. 2009 Jun;68(6):954-60
18490431
J Biol Chem. 2001 Feb 9;276(6):3983-90
11053440
Br J Pharmacol. 2012 Jun;166(4):1225-43
22364165
Intensive Care Med. 2012 Sep;38(9):1418-28
22706919
Int J Biol Markers. 2001 Oct-Dec;16(4):233-9
11820717
Best Pract Res Clin Rheumatol. 2005 Oct;19(5):685-708
16150398
J Intern Med. 2011 Jul;270(1):32-40
21332843
Hum Mol Genet. 2004 Jan 1;13(1):137-47
14645206
Clin Chem Lab Med. 2015 Oct;53(11):1799-805
25894644
Ann Rheum Dis. 1999 Aug;58(8):488-92
10419867
Clin Exp Rheumatol. 2013 Mar-Apr;31(2 Suppl 76):122-34
23910616
Biomarkers. 2012 Dec;17(8):758-63
23033975
Arthritis Rheum. 2011 Dec;63(12):3702-11
21953215